Pfizer Inc. (NYSE:PFE) Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 13.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,402,113 shares of the biopharmaceutical company's stock after purchasing an additional 1,231,296 shares during the quarter. Envestnet Asset Management Inc. owned about 0.18% of Pfizer worth $263,590,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Hexagon Capital Partners LLC boosted its holdings in shares of Pfizer by 4.3% in the 1st quarter. Hexagon Capital Partners LLC now owns 55,730 shares of the biopharmaceutical company's stock worth $1,412,000 after purchasing an additional 2,307 shares during the period. Investor s Fiduciary Advisor Network LLC boosted its holdings in shares of Pfizer by 16.5% in the 1st quarter. Investor s Fiduciary Advisor Network LLC now owns 29,207 shares of the biopharmaceutical company's stock worth $740,000 after purchasing an additional 4,141 shares during the period. Tradewinds LLC. boosted its holdings in shares of Pfizer by 21.8% in the 1st quarter. Tradewinds LLC. now owns 11,423 shares of the biopharmaceutical company's stock worth $289,000 after purchasing an additional 2,046 shares during the period. Meridian Investment Counsel Inc. boosted its holdings in Pfizer by 7.2% during the 1st quarter. Meridian Investment Counsel Inc. now owns 69,874 shares of the biopharmaceutical company's stock valued at $1,771,000 after acquiring an additional 4,717 shares during the period. Finally, McGlone Suttner Wealth Management Inc. boosted its holdings in Pfizer by 63.6% during the 1st quarter. McGlone Suttner Wealth Management Inc. now owns 20,023 shares of the biopharmaceutical company's stock valued at $507,000 after acquiring an additional 7,784 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on PFE. TD Cowen dropped their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. The Goldman Sachs Group boosted their price objective on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Redburn Atlantic dropped their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Stock Down 0.5%

NYSE PFE traded down $0.13 during trading on Friday, reaching $25.65. 34,838,317 shares of the company's stock were exchanged, compared to its average volume of 41,793,724. The stock has a market cap of $145.83 billion, a P/E ratio of 18.59, a price-to-earnings-growth ratio of 0.94 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a 50 day moving average price of $23.89 and a two-hundred day moving average price of $24.80. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the business earned $0.82 EPS. The business's quarterly revenue was down 7.8% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.71%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.